Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — EyePoint Pharmaceuticals — Investor Presentation (September 2022)
33 slides from Eyepoint's investor presentation, Sep 28, 2022
Slide 1: Investor Presentation September 28, 2022
Investor Presentation September 28, 2022 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activit
Slide 3: Company Overview: EYP-1901 is key pipeline program
EYP-1901 is key pipeline program Phase 2 “DAVIO 2” clinical trial in wet AMD underway Non-proliferative diabetic retinopathy (NPDR) “PAVIA” trial expected to begin in September 2022 Positive safety and efficacy data from Phase 1 “DAVIO” clinical trial Durasert® - proven intravitreal (IVT) drug deliv
Slide 4: Durasert Technology: Safe Sustained Intravitreal Drug Delivery
DURASERT® TECHNOLOGY 4 | INVESTOR PRESENTATION Safe Sustained Intravitreal Drug Delivery Used in four of six FDA approved intravitreal sustained delivery products Delivered by a single in-office IVT injection Continuous, stable release of drug Non-Erodible Products YUTIQ® (EyePoint) ILUVIEN® (Alimer
Slide 5: EYP-1901: Vorolanib in Bioerodible Durasert
EYP-1901 A single IVT injection of up to 3 inserts Bioerodible formulation of Durasert Initial drug burst from surface of insert to rapidly reach therapeutic levels in ocular tissues Zero order kinetics release Vorolanib Receptor-binding tyrosine kinase inhibitor (TKI) Binds receptors of all VEGF gr
Slide 6: EYP-1901 utilizes a bioerodible formulation of Durasert
EYP-1901 utilizes a bioerodible formulation of Durasert for repeated IVT injections Sustained, zero-order kinetics drug release over 6-9 months in bioerodible formulation High drug load per insert Single insert is ~1/5,000 the volume of the vitreous YUTIQ® Non-Erodible Silicone Seal v 3.5 mm EYP-190
Slide 7: Why Vorolanib?
Vorolanib selected after evaluation of over 100 small molecule TKIs Previously studied in Phase 1 and Phase 2 clinical trials as an oral therapy with compelling efficacy data and no ocular toxicity Intracellular binding of all VEGF receptors thereby blocking receptors of all VEGF family of growth fa
Slide 8: Vorolanib binds receptors of all VEGF growth factors
Vorolanib binds receptors of all VEGF growth factors with strong affinity to VEGF receptor 2 - a receptor associated with blood vessel leakage VOROLANIB VOROLANIB VOROLANIB VEGF-A VEGF-B VEGF-C VEGF-D R1 | Inflammation R2 | Blood Vessel Leakage R3 | Blood Vessel Growth & Leakage 8 | INVESTOR PRESENT
Slide 9: Phase 1 DAVIO Clinical Trial 12 Month Results
EYP-1901 PHASE 1 DAVIO CLINICAL TRIAL 12 MONTH RESULTS 9 | INVESTOR PRESENTATION
Slide 10: Phase 1 DAVIO clinical trial design
EYP-1901 Phase 1 DAVIO clinical trial enrolled 17 patients over four different dosages Primary Endpoint: Safety Ocular and non-ocular TEAEs through month-12 Secondary Endpoints Supplemental anti-VEGF therapy through 6-months Change in BCVA from baseline CST as measured by OCT RESULTS: MONTH 12 FULL
Slide 11: DAVIO demonstrated favorable overall safety at 12 months
EYP-1901 Phase 1 DAVIO clinical trial demonstrated favorable overall safety data at 12-months meeting primary endpoint Ocular AEs of particular interest: No vitreous floaters No endophthalmitis No retinal detachment No implant migration in the anterior chamber No retinal vasculitis No posterior segm
Slide 12: Treatment burden reduction of 75% at 6 months
EYP-1901 Phase 1 DAVIO clinical trial demonstrated clinically significant reduction in treatment burden of 75% at 6-months 12 | INVESTOR PRESENTATION DAVIO 12-month final data SOC Anti-VEGF Injections Before and After Treatment SOC (Anti-VEGF) + EYP-1901 Anti-VEGF No supplemental injection Missed vi
Slide 13: Treatment burden reduction of 73% at 12 months
EYP-1901 Phase 1 DAVIO clinical trial continues clinically significant reduction in treatment burden of 73% at 12-months 13 | INVESTOR PRESENTATION SOC Anti-VEGF Injections Before and After Treatment SOC (Anti-VEGF) + EYP-1901 Anti-VEGF No supplemental injection Missed visit Low dose (n=3) –66% Low-
Slide 14: 53% of patients did not require supplemental anti-VEGF at 6 months
EYP-1901 Phase 1 DAVIO clinical trial demonstrated that 53% of patients did not require supplemental anti-VEGF treatment at 6-months SUPPLEMENTAL ANTI-VEGF INJECTION-FREE RATE UP TO EACH VISIT MONTHS 14 | INVESTOR PRESENTATION n=17
Slide 15: Phase 1 DAVIO clinical trial met all objectives
EYP-1901 Phase 1 DAVIO clinical trial met all objectives FAVORABLE SAFETY PROFILE Stabilization of mean BCVA and OCT throughout 6 months was achieved 53% supplemental anti-VEGF injection free up to 6-months 79% reduction in treatment burden at 6-months No ocular SAEs reported No drug-related systemi
Slide 16: DAVIO Subset Analysis – Subjects with No Excess Fluid at Screening
DAVIO PHASE 1 CLINICAL TRIAL SUBSET ANALYSIS – SUBJECTS WITH NO EXCESS FLUID AT SCREENING (N=9) 16 | INVESTOR PRESENTATION EYP-1901
Slide 17: Mean change in BCVA and CST from screening visit
BCVA: best corrected visual acuity Mean change in BCVA from screening visit (n = 9) Mean change in CST from screening visit (n = 9) For 9 eyes at 6 months with no excess fluid at screening BCVA = +1.2 letters at 5 months -0.4 letters at 6 months CST on OCT = +20.8 microns at 5 months -1.0 microns at
Slide 18: Improved supplemental injection-free rates for subjects with no excess fluid
DAVIO Phase 1 clinical trial showed improved supplemental injection-free rates for subjects with no “excess fluid” at screening (n=9) Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12 % supplemental injection free “up to” each month 100% 100% 100% 89% 67% 67%
Slide 19: 92% reduction in treatment burden at 6 months among dry subjects
DAVIO Phase 1 clinical trial showed a 92% reduction in treatment burden at 6 months among subjects with no “excess fluid” at screening (n=9) SOC (Anti-VEGF) + EYP-1901 Low dose (n=2) -89% Low-mid dose (n=1) -100% Mid dose (n=5) -90% High dose (n=1) -100% SOC Anti-VEGF Injections Before and After Tre
Slide 20: Treat to Maintain
EYP-1901 TREAT TO MAINTAIN 20 | INVESTOR PRESENTATION
Slide 21: Treat to Maintain with EYP-1901
EYP-1901 demonstrated clinically significant reduction in treatment burden of 75% at 6 Months supporting treat to maintain positioning About half of eyes in DAVIO could go up to 6 months on EYP-1901 alone Another ~30% received only a single supplemental anti-VEGF during 6-months About 15 % failed bo
Slide 22: Positioned as a potential Treat-to-Maintain therapy in wet AMD
EYP-1901 positioned as a potential “Treat-to-Maintain” therapy in wet AMD Treat initially with current anti-VEGF standard of care until VA is maximally improved and retina is as dry as possible (induction phase) Maintain with EYP-1901 every six months, supplementing if needed with current anti-VEGF
Slide 23: Wet AMD Phase 2 Clinical Trial (DAVIO 2) EYP-1901
WET AMD PHASE 2 CLINICAL TRIAL (DAVIO 2) 23 | INVESTOR PRESENTATION EYP-1901
Slide 24: DAVIO 2 trial design
EYP-1901 DAVIO 2 clinical trial is non-pivotal randomized, double-masked, aflibercept controlled -D14 to -D7 D1 W4 W8 W12 W16 W24 W32 W36 to W56 W20 W28 EYP-1901 2mg low dose (n=48) EYP-1901 3mg high dose (n=48) Aflibercept q8W (n=48) RANDOMIZATION REQUIRED AFLIBERCEPT INJECTION VISIT VISIT SCHEDULE
Slide 25: NPDR Phase 2 Clinical Trial (PAVIA) EYP-1901
NPDR PHASE 2 CLINICAL TRIAL (PAVIA) 25 | INVESTOR PRESENTATION EYP-1901
Slide 26: PAVIA trial design
EYP-1901 Phase 2 NPDR PAVIA clinical trial is non-pivotal, randomized double-masked, day-one single injection with sham control EYP-1901 DOSING VISIT SCHEDULED SHAM INJECTION -D21 to –D5 D1 W4 W12 W24 W36 W48 EYP-1901 2mg low dose (n=35) EYP-1901 3mg high dose (n=35) Control Sham (n=35) RANDOMIZATIO
Slide 27: YUTIQ – An FDA Approved Product
YUTIQ – An FDA Approved Product
Slide 28: YUTIQ approved for posterior segment uveitis
Approved for the treatment of posterior segment uveitis Commercially launched in U.S. in 2019 Patent protection to August 2027 Constant and stable release of fluocinolone with Durasert helps prevent uveitis flares for up to 3 years LICENSE AGREEMENTS Alimera Sciences, Inc. has rights for non-infecti
Slide 29: Posterior segment uveitis causes blindness with every flare
PRODUCTS 60K–100K patients are suffering from posterior segment uveitis in the U.S. The need Flares can cause blindness 30,000 Americans become blind each year because of uveitis Uveitis lasts a lifetime and often affects people in middle age Conventional treatment is burdensome for patients and car
Slide 30: Continuous 3-year delivery limits blindness-causing flares
PRODUCTS CONTINUOUS CALM IN UVEITIS Continuous 3-year delivery limits blindness-causing flares Time to recurrence of uveitis within 36 months YUTIQ MEDIAN TIME TO FIRST RECURRENCE: 1051 DAYS PROBABILITY RECURRENCE 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 60 120 180 240 300 360 420 480 540 600 6
Slide 31: Record customer demand in 2Q 2022 for YUTIQ
Record customer demand in 2Q 2022 for YUTIQ 43% increase in Q2’22 compared to Q1’22 *Customer demand is defined as units purchased by Surgery Centers or physicians from the specialty distributors. PRODUCTS
Slide 32: Balance Sheet – June 30, 2022
Balance Sheet – June 30, 2022 $171 million of cash and investments $40 million of short and long-term debt Cash runway into 2H 2024 Solid cash position and growing revenues FINANCIAL SUMMARY Commercial Performance $11.3 million of net product revenues in Q2 2022, a 30% increase over Q2 2021 Commerci
Slide 33: Investor Presentation September 2022
Investor Presentation September 2022
EyePoint Pharmaceuticals — Investor Presentation (September 2022) on 6ix